You are here

P&T® Journal contents for October 2008


Cover Story
A comprehensive discussion of the causes, epidemiology, diagnosis, symptoms, and pharmacotherapy for this movement disorder is presented, with an emphasis on the efficacy and adverse effects of pharmaceutical treatments.
Marvin M. Goldenberg, PhD, RPh, MS
Health Care & Law
Although the intricacies of health care regulation may seem inefficient and unwieldy, our system of local, state, and national checks and balances actually makes a certain amount of sense. Dr. Field discusses the logic behind the ­complexities of the present regulatory system.
Robert I. Field, JD, MPH, PhD
Obama and McCain Positions Similar — with One Major Difference. The outlook for Medicare Part D and universal health insurance coverage may depend, in part, on who is elected President and how Congress decides to act.
Stephen Barlas
P&T Snapshot
The Multiple Sclerosis Trend Report reveals the need for many improvements in treating this expensive and complex disease, such as containing costs of biotech drugs, easing the process of obtaining patient reimbursements and physician ­payments, developing a role for specialty pharmacy, and eliminating barriers to patient–pharmacy communication.
Mari Edlin and Peter Sonnenreich, MA


David Nash, MD, MBA, talks about a new school of health policy to open next year at Thomas Jefferson University.
David B. Nash, MD, MBA
Medication Errors
Matthew Grissinger, RPh, FASCP, explains how easy it is to misprogram pumps used for patient-controlled analgesia.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Stephen Barlas discusses the need for Congress to fund a program to evaluate the cost effectiveness of drugs and medical devices.
Stephen Barlas
From Altace to Zyprexa, P&T presents the latest studies and information about FDA approvals, new indications, product recalls, and industry updates.
Drug Forecast
Dr. Erowele reviews alvim­opan, a mu-opioid receptor antagonist (Entereg), for postoperative ileus.
Goldina Ikezuagu Erowele, PharmD